Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Osprey Medical closes IPO raising of A$20 million

Osprey Medical Inc, has today announced that its Initial Public Offer (IPO) raising of A$20 million has closed. Osprey Medical’s Offer was well supported by institutional and retail investors in Australia, including founding investors CM Capital and Brandon Capital. The Initial Public Offer was underwritten by Shaw Corporate Finance.

17 Apr 2012

Novasep’s outstanding results in scale-up and biomanufacturing of Apo-A1 acknowledged by Cerenis at BioProcess International Conference

Novasep, a provider of purification-based manufacturing solutions for lifescience molecules, has announced that Cerenis Therapeutics has been invited by BioProcess International to present its major project CER – 001 ApoA1 - HDL mimetic drug candidate, and describe how Novasep played a critical role in the project by successfully achieving the transfer and scale up of Apo-A1 production.

16 Apr 2012

British doctors tackle the obesity epidemic

According to the Academy of Medical Royal Colleges the approach of using voluntary agreements with industry is “failing to have a significant impact” on obesity. Obesity, says the organization is a “huge crisis waiting to happen”.

16 Apr 2012

Men more likely to experience complications after brain or spinal surgery

Men are twice as likely as women to experience complications after brain or spinal surgery, reports a study in the April issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

16 Apr 2012

Changes in thromboxane synthase may lead to hypertension in women with preeclampsia

Virginia Commonwealth University School of Medicine researchers have discovered that changes in the gene expression of a key enzyme may contribute to high blood pressure and increase susceptibility to forming blood clots in pregnant women with preeclampsia.

16 Apr 2012

First study to show genetic adaptation of human fat metabolism

About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.

16 Apr 2012

New findings on out-of-hand nut consumption and health

In a study published in Nutrition Research, researchers looked at the association of out-of-hand nut (OOHN) consumption with nutrient intake, diet quality and the prevalence of risk factors for cardiovascular disease and metabolic syndrome in both children and adults.

16 Apr 2012

Mylan receives final FDA approval for generic Lescol Capsules ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fluvastatin Capsules USP, 20 mg and 40 mg, the first generic version of Novartis' Lescol Capsules.

16 Apr 2012

Flu shots offered to populations at risk at the beginning of season

All Care Inala Medical Centre doctor Michael Ho said flu shots were becoming more popular each year. “Flu seasons tends to begin in late March early April to June,” he said. “More and more people are opting to get vaccinations because they are promoted well within the community.” He added, “It is particularly important for elderly people to be immunized because their immune system is already not at its best…This is also the case for people who have chronic medical conditions like diabetes, severe asthma, or heart disease. With their current condition, if they catch the flu they can end up with a worse outcome.”

12 Apr 2012

KineMed receives NIH RAID grant to advance FX-5A for heart disease

KineMed Inc. today announced its successful award of a Rapid Access to Intervention Development (RAID) peer-reviewed grant by the National Institute of Health to advance an HDL mimetic, designated FX-5A, designed to reverse atherosclerosis and heart disease.

12 Apr 2012

Screen time linked with obesity in children

Approximately 20 percent of adolescents in the U.S. today are obese or overweight. With the number of obese and overweight younger children close behind, this epidemic has lasting implications for the future.

12 Apr 2012

Johns Hopkins cardiologists support use of statins for primary prevention of heart attack

Writing the first commentary for a new feature in the Journal of the American Medical Association (JAMA), called Viewpoint, Johns Hopkins cardiologists make the case for why a 55-year-old man with a 10 percent estimated risk of heart attack over the next 10 years should be offered statin medication. They were invited to debate a professor who argues against prescribing statins for "primary" prevention—for those who have not had a cardiovascular event, such as a heart attack—even though they may be considered at "intermediate" risk because of elevated cholesterol or other factors.

12 Apr 2012

ECG abnormalities associated with increased risk of CHD in older adults

In a study that included elderly men and women without preexisting cardiovascular disease, major and minor electrocardiographic abnormalities were associated with an increased risk of coronary heart disease (CHD) events and improved the prediction of CHD events such as heart attack, beyond traditional cardiovascular risk factors, according to a study in the April 11 issue of JAMA.

12 Apr 2012

ST2 more specific than BNP for heart failure diagnosis

Critical Diagnostics today announced publication in the latest issue of the Journal of Heart Failure results of a study involving 995 patients who presented to the emergency room (ER) with chest pain. The study concluded that in this undifferentiated, symptomatic patient population ST2 was more specific for acute heart failure than BNP and that ST2 is independently predictive of future death and/or heart failure and has incremental utility in combination with BNP.

12 Apr 2012

Takeda enters definitive agreement to acquire URL Pharma

Takeda Pharmaceutical Company Limited and URL Pharma Inc. jointly announced that Takeda's wholly-owned subsidiary, Takeda America Holdings, Inc. and URL Pharma have entered into a definitive agreement to acquire URL Pharma – a privately-held pharmaceutical company headquartered in Philadelphia, Pennsylvania, for an upfront payment of $800 million and future performance-based contingent earn out payments.

12 Apr 2012

University of Limerick researchers develop device to increase angioplasty success rates

Developed by biomedical engineers at the University of Limerick the device will improve success rates in angioplasty procedures. It is estimated that over 1 million angioplasty procedures are undertaken worldwide each year and the value of products relating to this procedure is in the region of €500million.

11 Apr 2012

Eye test to detect heart disease early

Scientists at the University of Edinburgh have developed the test which scans blood vessels in the retina at the back of the eyes. They are now launching a study involving more than 1,000 patients to see if the test is reliable.

11 Apr 2012

Fish oil not as beneficial for the heart as thought: Study

Fish oil, a combination of omega-3 fatty acids that has attracted much research on its effects on heart health. So far, the evidence has been inconclusive -- some studies have found fish oil has been major in preventing heart attacks, strokes and sudden cardiac death, while others have found fish oil has no benefits at all.

10 Apr 2012

DaVita introduces Kidney Smart website for patients with CKD

DaVita Inc., a leading provider of kidney care services that is committed to improving the quality of life for those diagnosed with chronic kidney disease (CKD), today announced the launch of its Kidney Smart website, for anyone with questions about CKD.

10 Apr 2012

Lee's Pharma licenses rights to commercialize PL2200 Aspirin in China

PLx Pharma Inc, a Houston based pharmaceutical company developing gastrointestinal (GI) safer drugs has licensed to Lee's Pharmaceutical Holdings Limited (Lee's Pharma) the rights to register and commercialize in China, Hong Kong and Macau the PL2200 Aspirin, a GI safer aspirin product currently in development in the US, for prevention of cardiovascular diseases. Cardiovascular is one of the focus areas of Lee's Pharma.

10 Apr 2012